Avoiding Needless Testing in NSCLC Treatment
With the emphasis on testing for biomarkers to determine treatment for patients with lung cancer, it's important to make sure the testing will have an impact on clinical decisions.
Olanzapine Significantly Reduces CINV in Patients Receiving MEC
Reimagining Frailty Screenings in Head and Neck Cancer
Screening for Pain and Depression is Not Enough in Cancer Care
Niraparib-Based Triplet Therapy Offers OS Advantage in BRCA1/2+ mCRPC
